CN1022323C - 从外消旋体中分离咪唑衍生物的d-对映体的方法 - Google Patents
从外消旋体中分离咪唑衍生物的d-对映体的方法 Download PDFInfo
- Publication number
- CN1022323C CN1022323C CN88104440A CN88104440A CN1022323C CN 1022323 C CN1022323 C CN 1022323C CN 88104440 A CN88104440 A CN 88104440A CN 88104440 A CN88104440 A CN 88104440A CN 1022323 C CN1022323 C CN 1022323C
- Authority
- CN
- China
- Prior art keywords
- enantiomorph
- medetomidine
- mixture
- gaonist
- separating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims description 7
- 150000002460 imidazoles Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 239000011833 salt mixture Substances 0.000 claims description 2
- 238000001640 fractional crystallisation Methods 0.000 claims 1
- HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 abstract description 18
- 229960002140 medetomidine Drugs 0.000 abstract description 18
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 11
- 229960002896 clonidine Drugs 0.000 description 9
- 238000011160 research Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000003513 alkali Substances 0.000 description 7
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- 206010039897 Sedation Diseases 0.000 description 5
- JXMXDKHEZLKQPB-UHFFFAOYSA-N detomidine Chemical compound CC1=CC=CC(CC=2[N]C=NC=2)=C1C JXMXDKHEZLKQPB-UHFFFAOYSA-N 0.000 description 5
- 229960001894 detomidine Drugs 0.000 description 5
- 229960002748 norepinephrine Drugs 0.000 description 5
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 5
- DEEPVUMBLJVOEL-UHFFFAOYSA-N 3H-pyrazole Chemical class C1C=CN=N1 DEEPVUMBLJVOEL-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000004899 motility Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 229940095064 tartrate Drugs 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 2
- 102000017910 Adrenergic receptor Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100108551 Mus musculus Akr1b7 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000863032 Trieres Species 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 229940044170 formate Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- -1 vitriol Chemical compound 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Optical Record Carriers And Manufacture Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Photoreceptors In Electrophotography (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8716803A GB2206880B (en) | 1987-07-16 | 1987-07-16 | Optical isomers of an imidazole derivative |
| GB8716803 | 1987-07-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1030576A CN1030576A (zh) | 1989-01-25 |
| CN1022323C true CN1022323C (zh) | 1993-10-06 |
Family
ID=10620775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN88104440A Expired - Lifetime CN1022323C (zh) | 1987-07-16 | 1988-07-16 | 从外消旋体中分离咪唑衍生物的d-对映体的方法 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US4910214A (enExample) |
| EP (1) | EP0300652B1 (enExample) |
| JP (1) | JPH0625138B2 (enExample) |
| KR (1) | KR940007311B1 (enExample) |
| CN (1) | CN1022323C (enExample) |
| AT (1) | ATE71941T1 (enExample) |
| AU (1) | AU600839B2 (enExample) |
| BG (1) | BG60473B2 (enExample) |
| CA (1) | CA1337659C (enExample) |
| CY (2) | CY1787A (enExample) |
| DD (1) | DD281807A5 (enExample) |
| DE (2) | DE10399005I2 (enExample) |
| DK (1) | DK165788C (enExample) |
| ES (1) | ES2038757T3 (enExample) |
| FI (1) | FI95375C (enExample) |
| GB (1) | GB2206880B (enExample) |
| GR (1) | GR3003878T3 (enExample) |
| HK (1) | HK56094A (enExample) |
| HU (1) | HU198693B (enExample) |
| IE (1) | IE60456B1 (enExample) |
| IL (1) | IL87076A0 (enExample) |
| LU (1) | LU91010I2 (enExample) |
| NL (1) | NL300117I2 (enExample) |
| NO (2) | NO170579C (enExample) |
| NZ (1) | NZ225362A (enExample) |
| PT (1) | PT88013B (enExample) |
| SU (1) | SU1648248A3 (enExample) |
| UA (1) | UA5560A1 (enExample) |
| ZA (1) | ZA885134B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102464619A (zh) * | 2010-11-17 | 2012-05-23 | 桑迪亚医药技术（上海）有限责任公司 | 一种左旋4-[1-(2,3-二甲基苯基)乙基]-1r-咪唑消旋化方法 |
| CN105175339A (zh) * | 2015-10-09 | 2015-12-23 | 辰欣药业股份有限公司 | 一种制备盐酸右美托咪定的方法 |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2215206B (en) * | 1988-02-29 | 1991-07-03 | Farmos Oy | 4-substituted imidazole derivatives useful in perioperative care |
| US5124157A (en) * | 1989-08-18 | 1992-06-23 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
| US5120713A (en) * | 1990-09-10 | 1992-06-09 | Applied Research Systems Ars Holding N.V. | Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide |
| GB9111732D0 (en) * | 1991-05-31 | 1991-07-24 | Orion Yhtymae Oy | The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs |
| GB2281206A (en) * | 1993-08-25 | 1995-03-01 | Orion Yhtymae Oy | Use of dexmedetomidine |
| GB9425211D0 (en) * | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| IN187238B (enExample) * | 1995-06-30 | 2002-03-09 | Astra Ab | |
| GB9521680D0 (en) * | 1995-10-23 | 1996-01-03 | Orion Yhtymo Oy | New use of imidazole derivatives |
| US5866579A (en) * | 1997-04-11 | 1999-02-02 | Synaptic Pharmaceutical Corporation | Imidazole and imidazoline derivatives and uses thereof |
| AR015744A1 (es) * | 1998-04-01 | 2001-05-16 | Orion Corp | Uso de dexmedetomidina para sedacion en terapia intensiva |
| US6716867B1 (en) | 1998-04-01 | 2004-04-06 | Orion Corporation | Use of dexmedetomidine for ICU sedation |
| AU778522B2 (en) | 1999-10-29 | 2004-12-09 | Orion Corporation | Treatment or prevention of hypotension and shock |
| US6388090B2 (en) * | 2000-01-14 | 2002-05-14 | Orion Corporation | Imidazole derivatives |
| US7141597B2 (en) * | 2003-09-12 | 2006-11-28 | Allergan, Inc. | Nonsedating α-2 agonists |
| AU2006311577B2 (en) | 2005-11-09 | 2013-02-07 | Zalicus Inc. | Methods, compositions, and kits for the treatment of medical conditions |
| ATE536867T1 (de) | 2006-03-16 | 2011-12-15 | Tris Pharma Inc | Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen |
| US7795263B2 (en) * | 2008-07-08 | 2010-09-14 | Wildlife Laboratories, Inc. | Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals |
| EP2370136A4 (en) * | 2008-12-01 | 2015-12-30 | Map Pharmaceuticals Inc | INHALATIVE RELEASE PROCEDURES AND DEVICES |
| WO2010074753A1 (en) | 2008-12-23 | 2010-07-01 | Map Pharmaceuticals, Inc. | Inhalation devices and related methods for administration of sedative hypnotic compounds |
| US20110021588A1 (en) * | 2009-05-15 | 2011-01-27 | Recro Pharma, Inc. | Sublingual dexmeditomidine compositions and methods of use thereof |
| CN101671305A (zh) * | 2009-09-29 | 2010-03-17 | 北京华禧联合科技发展有限公司 | 一种拆分美托咪定的左旋及右旋对映体的方法 |
| US20130096170A1 (en) | 2011-10-14 | 2013-04-18 | Hospira, Inc. | Methods of treating pediatric patients using dexmedetomidine |
| WO2013069025A1 (en) | 2011-11-11 | 2013-05-16 | Neon Laboratories Ltd. | "process for the preparation of dexmedetomidine" |
| SG10201604653TA (en) | 2011-12-11 | 2016-07-28 | Recro Pharma Inc | Intranasal dexmedetomidine compositions and methods of use thereof |
| US8242158B1 (en) | 2012-01-04 | 2012-08-14 | Hospira, Inc. | Dexmedetomidine premix formulation |
| ITMI20120311A1 (it) * | 2012-02-29 | 2013-08-30 | Edmond Pharma Srl | Procedimento per la risoluzione di medetomidina e recupero dell'enantiomero indesiderato |
| CA2880456A1 (en) | 2012-08-15 | 2014-02-20 | Tris Pharma, Inc. | Methylphenidate extended release chewable tablet |
| DK2906213T3 (en) | 2012-10-15 | 2018-02-19 | Orion Corp | VETERINARY PROCEDURE FOR RELIEFING NOISE SENSITIVITY |
| TWI645866B (zh) | 2013-10-07 | 2019-01-01 | 美商帝國製藥美國股份有限公司 | 右美托咪啶經皮輸送裝置及使用其之方法 |
| US20150098997A1 (en) | 2013-10-07 | 2015-04-09 | Teikoku Pharma Usa, Inc. | Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions |
| JP6188933B2 (ja) | 2013-10-07 | 2017-08-30 | テイコク ファーマ ユーエスエー インコーポレーテッド | 非鎮静量のデクスメデトミジンの経皮送達用方法及び組成物 |
| US9717796B1 (en) | 2016-04-20 | 2017-08-01 | Slypharma, Llc | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container |
| FR3054218B1 (fr) * | 2016-07-22 | 2020-03-06 | Universite De Rouen | Procede de dedoublement de sels de baclofene |
| RU2723761C1 (ru) | 2016-10-31 | 2020-06-17 | ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. | Способы устранения боли с использованием устройств для трансдермальной доставки дексмедетомидина |
| US11160791B2 (en) | 2018-11-01 | 2021-11-02 | Medefil, Inc. | Dexmedetomidine injection premix formulation in ready to use (RTU) bags |
| CN115197149B (zh) * | 2021-04-02 | 2023-09-22 | 四川大学华西医院 | 一种5-苄基咪唑类化合物及其制备方法和用途 |
| CN114671811A (zh) * | 2022-04-14 | 2022-06-28 | 南京正科医药股份有限公司 | 一种右美托咪定拆分副产物的外消旋化回收方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU518569B2 (en) * | 1979-08-07 | 1981-10-08 | Farmos-Yhtyma Oy | 4-benzyl- and 4-benzoyl imidazole derivatives |
| GB2092569B (en) * | 1981-02-05 | 1984-09-19 | Farmos Oy | Substituted imidazole derivatives and their preparation and use |
| GB2101114B (en) | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
| FI844786A0 (fi) | 1984-12-04 | 1984-12-04 | Farmos Oy | Terapeutiskt utnyttjbar foerening. |
| DE3531682A1 (de) * | 1985-09-05 | 1987-03-12 | Thomae Gmbh Dr K | (+)-6-chlor-5,10-dihydro-5-((1-methyl-4- piperidinyl)acetyl)-11h-dibenzo(b,e)(1,4) diazepin-11-on, seine isolierung und verwendung als arzneimittel |
-
1987
- 1987-07-16 GB GB8716803A patent/GB2206880B/en not_active Expired - Lifetime
-
1988
- 1988-06-14 FI FI882819A patent/FI95375C/fi active Protection Beyond IP Right Term
- 1988-06-28 UA UA4356076A patent/UA5560A1/uk unknown
- 1988-06-28 SU SU884356076A patent/SU1648248A3/ru active
- 1988-07-08 AT AT88306250T patent/ATE71941T1/de active
- 1988-07-08 ES ES198888306250T patent/ES2038757T3/es not_active Expired - Lifetime
- 1988-07-08 DE DE2003199005 patent/DE10399005I2/de active Active
- 1988-07-08 EP EP88306250A patent/EP0300652B1/en not_active Expired - Lifetime
- 1988-07-08 DE DE8888306250T patent/DE3867945D1/de not_active Expired - Lifetime
- 1988-07-11 NZ NZ225362A patent/NZ225362A/xx unknown
- 1988-07-11 DK DK386288A patent/DK165788C/da not_active IP Right Cessation
- 1988-07-11 AU AU18941/88A patent/AU600839B2/en not_active Expired
- 1988-07-12 IL IL87076A patent/IL87076A0/xx not_active IP Right Cessation
- 1988-07-14 CA CA000572086A patent/CA1337659C/en not_active Expired - Lifetime
- 1988-07-14 DD DD88317936A patent/DD281807A5/de not_active IP Right Cessation
- 1988-07-15 KR KR1019880008937A patent/KR940007311B1/ko not_active Expired - Lifetime
- 1988-07-15 IE IE217488A patent/IE60456B1/en not_active IP Right Cessation
- 1988-07-15 PT PT88013A patent/PT88013B/pt not_active IP Right Cessation
- 1988-07-15 US US07/219,637 patent/US4910214A/en not_active Expired - Lifetime
- 1988-07-15 NO NO883155A patent/NO170579C/no not_active IP Right Cessation
- 1988-07-15 HU HU883708A patent/HU198693B/hu unknown
- 1988-07-15 ZA ZA885134A patent/ZA885134B/xx unknown
- 1988-07-16 CN CN88104440A patent/CN1022323C/zh not_active Expired - Lifetime
- 1988-07-16 JP JP63177959A patent/JPH0625138B2/ja not_active Expired - Lifetime
-
1992
- 1992-02-21 GR GR920400299T patent/GR3003878T3/el unknown
-
1994
- 1994-01-18 BG BG098380A patent/BG60473B2/bg unknown
- 1994-05-24 HK HK56094A patent/HK56094A/en not_active IP Right Cessation
-
1995
- 1995-10-20 CY CY178795A patent/CY1787A/xx unknown
-
2003
- 2003-02-14 LU LU91010C patent/LU91010I2/fr unknown
- 2003-03-03 NL NL300117C patent/NL300117I2/nl unknown
- 2003-07-01 NO NO2003004C patent/NO2003004I2/no unknown
-
2004
- 2004-10-27 CY CY200400006C patent/CY2004006I2/el unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102464619A (zh) * | 2010-11-17 | 2012-05-23 | 桑迪亚医药技术（上海）有限责任公司 | 一种左旋4-[1-(2,3-二甲基苯基)乙基]-1r-咪唑消旋化方法 |
| CN105175339A (zh) * | 2015-10-09 | 2015-12-23 | 辰欣药业股份有限公司 | 一种制备盐酸右美托咪定的方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1022323C (zh) | 从外消旋体中分离咪唑衍生物的d-对映体的方法 | |
| CN1087340A (zh) | 哌啶衍生物及其制备和在治疗学上的应用 | |
| CZ290115B6 (cs) | Farmaceutický prostředek | |
| CN1454054A (zh) | 用(r)－奥昔布宁和(r)－去乙基奥昔布宁治疗平滑肌机能亢进 | |
| CN1324239A (zh) | 镇痛剂 | |
| TW201338772A (zh) | 藥學組合物 | |
| CN1226175A (zh) | 吸收促进剂 | |
| CN1085979C (zh) | 麻药型镇痛剂依赖性/抗性形成抑制剂 | |
| US20200215068A1 (en) | Treatment of type i and type ii diabetes | |
| CN1249682A (zh) | 用于治疗有症状的心力哀竭的血管紧张素ⅱ拮抗剂 | |
| EP1315488A2 (en) | Pharmaceutical compositions containing aminothiazole derivatives for the treatment of colonic motor dysfunctions | |
| CN1120934A (zh) | 青光眼治疗剂及眼压降低剂 | |
| CN1498109A (zh) | 膀胱感觉过敏治疗剂 | |
| CN1592615A (zh) | 含有二甲双胍和4－氧代丁酸的药物组合物及其在治疗糖尿病中的用途 | |
| JP2012513443A5 (enExample) | ||
| CN1033809A (zh) | 6-氯-4-羟基-2-甲基-N-(2-吡啶基)-2H-噻吩并(2，3-e)-1，2-噻嗪-3-羧基酰胺1，1-二氧化物烯醇醚类化合物，其制备方法及应用 | |
| CN1268395C (zh) | 慢性肾脏疾病治疗药物 | |
| CN1276753C (zh) | 用于治疗类阿片依赖性的吡啶－2－基－甲胺衍生物 | |
| CN1290581C (zh) | 高血压症治疗药 | |
| CN1048381A (zh) | [α-(叔丁基氨基甲基)-3，4-二氯苄基]硫代乙酰胺，其制备方法及应用 | |
| CN1699370A (zh) | 青蒿琥酯盐及其制备方法和应用 | |
| CN1708308A (zh) | 福辛普利降低透析患者心血管事件的用途 | |
| KR820001304B1 (ko) | 펜아탄올아민의 제조방법 | |
| CN1589154A (zh) | 含有血管紧张肽ii受体拮抗剂的药用组合物 | |
| EP0473285A1 (en) | Use of 2-(phenoxypropanolamino)ethoxyphenoxyacetic acid and its derivatives to inhibit gastrointestinal motility |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C15 | Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993) | ||
| OR01 | Other related matters | ||
| C17 | Cessation of patent right | ||
| CX01 | Expiry of patent term |